Thus, inhibiting the inflammatory mediators (IL-6, G-CSF) or downstream MEK signaling prevented chemotherapy (DTX)-induced breast cancer dormancy awakening and ameliorated a potentially tumor immunosuppressive microenvironment. The gene discussed is MAP2K7; the disease is breast carcinoma.